Danjuma et al., Does Colchicine Reduce Mortality in Patients with Covid-19 Clinical Syndrome? An Umbrella Review of Published.., Elsevier BV, doi:10.2139/ssrn.4447127 (Preprint), PROSPERO CRD42023397246
Umbrella review of 18 colchicine meta analyses, showing significantly lower COVID-19 mortality with colchicine.Currently there are 48 colchicine studies and meta analysis shows:
Abstract: review of published meta-analyses
iew
ed
Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? an umbrella
Mohammed I Danjuma 1,2,3, Rana Sayed4, Maryam Aboughalia4, Aseel Hassona4, Basant
Selim Elsayed4, Mohamed Elshafei5, Abdelnaser Elzouki1,2,4
1. Department of Internal Medicine, Hamad Medical Corporation, Doha Qatar
ev
2. Department of Internal Medicine, Weill Cornell College of Medicine, New York,
and Doha Qatar
3. NHS Grampian (Dr Grays Hospital)
er
r
4. Department of Internal Medicine, Qatar University College of Medicine
rin
tn
ot
pe
5. Department of Pharmacy, Hamad Medical Corporation, Doha Qatar
Corresponding author:
Dr. Mohammed Ibn-Mas’ud Danjuma
ep
Consultant Physician and Clinical Pharmacologist
Department of Internal Medicine, Weill Cornell College of Medicine
New York and Doha Qatar
Pr
Email: mdanjuma21@gmail.com; mdanjuma@hamad.qa
1
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4447127
iew
ed
Abstract
Background
Despite significant improvements in both treatment and prevention strategies, as well as
multiple commissioned reviews, there remains uncertainty regarding the survival benefit of
repurposed drugs such as colchicine in patients with Covid-19 clinical syndrome.
ev
Methods:
In this umbrella review, we carried out a comprehensive search of PubMed, EMBASE,
Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of
er
r
Abstracts of Reviews of Effectiveness between 1st January 2020 and 31st January 2023 for
systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine
in patients with Covid-19. This was to ascertain the exact relationship between colchicine
pe
exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool
to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality
and risk of bias assessment of the included reviews.
ot
Results:
We included eighteen meta-analyses (n = 199,932 participants) in this umbrella review.
tn
Colchicine exposure was associated with an overall reduction of about 35% in the risk of
mortality (odds ratio 0.68, confidence interval [CI] 0.58-0.78; I2 = 94%, p = 0.001). Further
examination of pooled estimates of mortality outcomes by the quality effects model (corrected
rin
for the methodological quality and risk of bias of the constituent reviews) reported similar point
estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%).
ep
Conclusion:
In a pooled umbrella evaluation of published meta-analyses of Covid-19 patient cohorts,
exposure to colchicine was associated with a reduction in overall mortality. Although it remains
Pr
uncertain if this effect could potentially be attenuated or augmented by Covid-19 vaccination.
PROSPERO Registration number: CRD42023397246.
2
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4447127
iew
ed
Key words: COVID-19; Colchicine; Meta-analysis; Mortality; Umbrella
Background
Successful immunization with a variety of approved Coronavirus Disease 2019 (COVID-19)
vaccines has significantly contributed to containing both the spread and the adverse
consequences of this nascent infection. However, the exact role of clinical therapeutics in its
management is still evolving. Since the onset of the COVID-19 pandemic, repurposing of drugs
ev
with..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.